title: [Development of serous retinopathy during therapy of a metastatic cutaneous melanoma].
abstract: Inhibitors of the mitogen-activated protein kinase (MAPK) signal pathway have decisively improved the prognosis of metastatic cutaneous melanoma in patients with an activating mutation in position V600 of the BRAF gene. We report on a patient who was regularly examined in our clinic while participating in a randomized blinded clinical trial. The aim of this trial was to examine the effectiveness and tolerability of a combination of the BRAF inhibitor dabrafenib and the MAPK kinase (MEK) inhibitor trametinib compared with a monotherapy with dabrafenib (plus placebo). During therapy the patient developed a diffuse neuroretinal detachment which could not be completely reversed after discontinuation of the study medication.
authors.affiliation: Klinik und Poliklinik für Augenheilkunde, Universitätsklinikum Schleswig Holstein, Campus Lübeck, Ratzeburger Allee 160, 23562, Lübeck, Deutschland. inger.luedeke@rwth-aachen.de.
authors.forename: I
authors.initials: I
authors.lastname: Lüdeke
authors.affiliation: Hautkrebszentrum Lübeck, Klinik für Dermatologie, Allergologie und Venerologie, Universitätsklinikum Schleswig-Holstein, Campus Lübeck, Lübeck, Deutschland.
authors.forename: P
authors.initials: P
authors.lastname: Terheyden
authors.affiliation: Klinik und Poliklinik für Augenheilkunde, Universitätsklinikum Schleswig Holstein, Campus Lübeck, Ratzeburger Allee 160, 23562, Lübeck, Deutschland.
authors.forename: S
authors.initials: S
authors.lastname: Grisanti
authors.affiliation: Klinik und Poliklinik für Augenheilkunde, Universitätsklinikum Schleswig Holstein, Campus Lübeck, Ratzeburger Allee 160, 23562, Lübeck, Deutschland.
authors.forename: M
authors.initials: M
authors.lastname: Lüke
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects*; D056833:Central Serous Chorioretinopathy / Q000139:chemically induced* / Q000175:diagnosis* / Q000517:prevention & control; D003937:Diagnosis, Differential; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage / Q000009:adverse effects; D008545:Melanoma / Q000150:complications / Q000188:drug therapy* / Q000556:secondary*; D008875:Middle Aged; D010091:Oximes / Q000008:administration & dosage / Q000009:adverse effects; D011728:Pyridones / Q000008:administration & dosage / Q000009:adverse effects; D011744:Pyrimidinones / Q000008:administration & dosage / Q000009:adverse effects; D016037:Single-Blind Method; D012878:Skin Neoplasms / Q000150:complications / Q000188:drug therapy*; D016896:Treatment Outcome
chemical_list: D007093:Imidazoles; D010091:Oximes; D011728:Pyridones; D011744:Pyrimidinones; C560077:trametinib; C561627:dabrafenib
keywords: BRAF inhibitor; Chorioretinopathy; Dabrafenib; MEK inhibitor; Trametinib